← Back to home

Non-small cell lung cancer (NSCLC, locally advanced or metastatic, second-line

Clinical trials for Non-small cell lung cancer (NSCLC, locally advanced or metastatic, second-line explained in plain language.

Never miss a new study

Get alerted when new Non-small cell lung cancer (NSCLC, locally advanced or metastatic, second-line trials appear

Sign up with your email to follow new studies for Non-small cell lung cancer (NSCLC, locally advanced or metastatic, second-line, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

Can a drug duo outsmart resistant lung cancer?

Disease control Not yet recruiting

This phase II trial is testing whether combining two targeted drugs—andamertinib and anlotinib—can help people with advanced non-small cell lung cancer whose tumors have grown despite prior treatment with a third-generation EGFR inhibitor. The study enrolls adults with locally ad…

Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC, LOCALLY ADVANCED OR METASTATIC, SECOND-LINE

Phase 2 • Sponsor: Fudan University • Aim: Disease control

Last updated Aug 27, 2026 00:00 UTC

Non-small cell lung cancer (NSCLC, locally advanced or metastatic, second-line

Get alerted when new Non-small cell lung cancer (NSCLC, locally advanced or metastatic, second-line trials appear

Can a drug duo outsmart resistant lung cancer?